# Globus Medical Inc. (GMED) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Medical Devices & Supplies. Price $79.58, market value $10.7 billion.

## Valuation
- **P/E (trailing): 20.4×** (5-yr avg 54.5×, 3-yr avg 60.8×). Globus Medical Inc. trades at 20.4× trailing earnings, well below its own five-year average of 54.5×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 14.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.03**. A PEG of 0.03 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.4×**. Each dollar of revenue is priced at 3.4×.
- **Price / book: 2.2×**. The shares trade at 2.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 7.1%** (5-yr avg 3.1%). Free cash flow equals 7.1% of the market value, above its five-year average of 3.1%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 4.9%**. The inverse of the P/E: 4.9% of the price is earned each year.

## Profitability
- **Operating margin: 20.3%**. 20.3% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 18.3%**. 18.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 11.8%**. 11.8% on shareholders' equity is solid.
- **Return on assets: 10.1%**. Each dollar of assets produces 10.1% of profit.

## Growth
- **Revenue growth (1 yr): 16.7%** (3-yr 42.2%/yr, 5-yr 30.1%/yr). Revenue grew 16.7% over the last year, against 30.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 422.7%** (3-yr 28.4%/yr, 5-yr 31.2%/yr). Earnings per share rose 422.7%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 78.0%/yr**. Free cash flow has compounded at 78.0% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Current ratio: 4.26** (quick 4.26). Current assets cover the next year's liabilities 4.26 times.
- **Altman Z-score: 11.22**. A Z-score of 11.22 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Globus Medical Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (13 analysts). 13 analysts cover Globus Medical Inc.; the consensus is buy, with an average price target of $100.92 (+27% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 31.6%** (YTD -9.0%, 3-mo -2.5%). The shares are up 31.6% over twelve months including dividends.
- **From 52-week high: -21.5%** (32.1% above the low). Trading 22% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 0.80** (volatility 49%). Beta of 0.80 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GMED · Page: https://foliofundamentals.com/stocks/gmed

Not investment advice.